Immune Infiltrates in Breast Cancer: Recent Updates and Clinical ImplicationsMaria Vittoria Dieci, Valentina Guarneri, Federica Miglietta|Cells|2021Cited by 227
Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2021Cited by 226
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Tomás Pascual et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?Maria Vittoria Dieci, Valentina Guarneri, Gaia Griguolo et al.|Cancer Treatment Reviews|2016Cited by 128
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing PerspectivesLuisa Carbognin, Maria Vittoria Dieci, Federica Miglietta et al.|Cancers|2019Cited by 115